Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an
intravenous blocker of the adenosine diphosphate receptor P2Y12. This agent might have a …

Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Background: Standard administration of newer oral P2Y12 inhibitors, including prasugrel or
ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with …

The platelet, once thought to be solely involved in clot formation, is now known to be a key
mediator in various others processes such as inflammation, thrombosis, and atherosclerosis …

In the normal course of the delivery of care, anesthesiologists encounter many patients who
are receiving drugs that affect platelet function as a fundamental part of primary and …

phoprotein (VASP) assay, which specifically explores the function of platelet P2Y12. These
patients were randomized to undergo VASP-guided additional loading doses of 600 mg …

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing.
Development of these new agents was prompted by limitations of existing antiplatelet …

Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective
and irreversible blockade of the P2Y12 receptor. Combination antiplatelet therapy with …